Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 3,581 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Altimmune Inc | ALT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.047 | -0.65% | 7.153 | 08:17:54 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.20 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 55 | 3,581 | - | 2.09 - 14.84 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:18:57 | 50 | $ 7.17 | USD |
Altimmune (ALT) Options Flow Summary
Altimmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 386.85M | 53.73M | - | 426k | -88.45M | -1.65 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Altimmune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.85 | 8.23 | 6.64 | 7.24 | 2,692,024 | 0.303 | 4.42% |
| 1 Month | 10.25 | 11.01 | 6.64 | 8.16 | 3,018,995 | -3.10 | -30.21% |
| 3 Months | 9.61 | 14.84 | 6.64 | 9.99 | 4,736,954 | -2.46 | -25.57% |
| 6 Months | 2.65 | 14.84 | 2.24 | 7.95 | 7,802,894 | 4.50 | 169.92% |
| 1 Year | 5.24 | 14.84 | 2.09 | 7.26 | 4,620,402 | 1.91 | 36.51% |
| 3 Years | 12.73 | 23.49 | 2.09 | 8.91 | 2,551,545 | -5.58 | -43.81% |
| 5 Years | 2.69 | 35.10 | 1.45 | 10.14 | 2,140,605 | 4.46 | 165.91% |
Altimmune Description
| Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). |
